(NASDAQ: BCTX) Briacell Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Briacell Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BCTX's revenue for 2027 to be $161,415,433, with the lowest BCTX revenue forecast at $161,415,433, and the highest BCTX revenue forecast at $161,415,433. On average, 1 Wall Street analysts forecast BCTX's revenue for 2028 to be $565,753,100, with the lowest BCTX revenue forecast at $565,753,100, and the highest BCTX revenue forecast at $565,753,100.
In 2029, BCTX is forecast to generate $1,166,665,998 in revenue, with the lowest revenue forecast at $1,166,665,998 and the highest revenue forecast at $1,166,665,998.